Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the 3rd quarter, Holdings Channel reports. The firm owned 305,507 shares of the biopharmaceutical company’s stock after buying an additional 4,010 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Gilead Sciences were worth $24,752,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Hanson & Doremus Investment Management grew its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences in the 2nd quarter valued at $147,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV acquired a new position in Gilead Sciences in the 2nd quarter valued at $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new position in Gilead Sciences in the 2nd quarter valued at $172,000. Institutional investors own 75.94% of the company’s stock.
Gilead Sciences, Inc. (GILD) opened at $79.02 on Monday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The stock has a market cap of $103,190.00, a PE ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.
The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.63%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
A number of analysts have weighed in on the stock. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group reissued a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $85.03.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock valued at $34,072,567 over the last three months. 1.30% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with our FREE daily email newsletter.